APAC Taxane Market - Industry Trends and Forecast to 2029

APAC Taxane Market - Industry Trends and Forecast to 2029

Asia-Pacific taxane market is projected to register a substantial CAGR of 8.7% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2021, the base year of calculation is 2022 and the forecast period is 2022 to 2029.
Market Segmentation
Asia-Pacific Taxane Market, By Type (Paclitaxel, Docetaxel, Cabazitaxel), Drug Type (Generics, Branded), Formulation (Liposomes, Nanoparticles, Polymeric Micelles, Others), Age Group (Adults, Geriatric), Application (Breast Cancer, Non-Small Lung Cancer, Pancreatic Cancer, Ovarian Cancer, Prostate Cancer, Others), End User (Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Others) Distribution Channel (Retail Sales, Direct Tender), Country (China, Japan, India, South Korea, Singapore, Thailand, Vietnam, Malaysia, Indonesia, Philippines, Rest of Asia-Pacific) Industry Trends and Forecast to 2029

Some of the major factors contributing to the growth of the Asia-Pacific taxane market are:
• The rise in incidence of cancer
• The funding by the government and investment in research and development
Market Segmentation
Asia-Pacific taxane market is categorized into seven notable segment which is type, drug type, formulation, age group, application, end user and distribution channel.
• On the basis of type, the Asia-Pacific taxane market is segmented into paclitaxel, docetaxel and cabazitaxel.
• On the basis of application, the Asia-Pacific taxane market is segmented into ovarian cancer, breast cancer, prostate cancer, non-small cell lung cancer and other
• On the basis of drug type, the Asia-Pacific taxane market is segmented into branded and generics
• On the basis of formulation, the Asia-Pacific taxane market is segmented into liposomes, nanoparticles, polymeric micelles and others
• On the basis of age group, the Asia-Pacific taxane market is segmented into adults and geriatric
• On the basis of end user, the Asia-Pacific taxane market is segmented into hospitals, ambulatory surgical centers, specialty clinics, and others
• On the basis of distribution channel, the Asia-Pacific taxane market is segmented into direct tender, retail sales

Market Players

The key market players for Asia-Pacific taxane market are listed below:
• Viatris Inc.
• Sandoz International GmbH (A Novartis Division)
• sanofi-aventis U.S. LLC
• Hikma Pharmaceuticals PLC
• Pfizer Inc.
• Dr. Reddy’s Laboratories Ltd.
• Taxane Healthcare
• Bristol-Myers Squibb Company
• Fresenius Kabi AG (Subsidiary of Fresenius SE & Co. KGaA)
• SAMYANG HOLDINGS CORPORATION.
• Luye Pharma Group
• Elevar Therapeutics
• Huiang Pharmaceutical Co Ltd.
• Shenzhen Main Luck Pharmaceuticals Inc.
• Accord Healthcare
• Torrent Pharmaceuticals Ltd.
• Panacea Biotec
• RPG Life Sciences Limited.
• Aureate Healthcare
• Samarth Life Sciences Pvt. Ltd.
• Cipla Inc.
• Hetero Healthcare Limited.
• Ingenus Pharmaceuticals, LLC

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.

Please note: This publisher does offer titles that are created upon receipt of order. The report will take approximately 15-20 business days to prepare and deliver.